Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory... by Tremblay G, Livings C, Crowe L, Kapetanakis V, Briggs A

Connect to this object online.

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia by Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, Briggs A

Connect to this object online.

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness usi... by Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A

Connect to this object online.

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia by Tremblay G, Dolph M, Bhor M, Said Q, Roy A, Elliott B, Briggs A

Connect to this object online.